Imquest Life News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Statera BioPharma, Inc Provides Update on Integration of ImQuest
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Statera BioPharma, Inc Provides Update on Integration of ImQuest
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
FORT COLLINS, Colo., April 20, 2021 /PRNewswire/ Cytocom, Inc. (Cytocom), a leading biopharmaceutical company creating next generation immune therapies built around proprietary discovery and development technologies, today announced that Stephen Wilson, Ph.D., has joined the company as its Head of Global Innovations, effective April 19, 2021. Dr. Wilson arrives at Cytocom after spending nearly 25 years at the La Jolla Institute for Immunology (LJII) where he was active in biomedical research and served as the research facility s chief operating officer.
As Head of Global Innovation for Cytocom, Dr. Wilson will help identify new indications for Cytocom s existing pipeline of assets designed to rebalance the body s immune system and restore homeostasis and lead efforts to develop a global network of researchers and scientists to collaborate with Cytocom in new applications for its AIMS™ (Advanced Immunomodulating Multi-Receptor System) dr
Cleveland BioLabs, Inc. Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc.
Combined public entity to develop and commercialize next-generation immune therapies that address unmet needs in oncology, infectious disease, inflammation and auto-immune-mediated conditions
FORT COLLINS, CO and BUFFALO, NY / ACCESSWIRE / February 17, 2021 / Cleveland BioLabs, Inc. (NASDAQ:CBLI), an innovative biopharmaceutical company developing novel approaches to activate the immune system, filed a registration statement on Form S-4 (the Registration Statement ) with the U.S. Securities and Exchange Commission (SEC) in connection with its previously announced merger agreement with Cytocom, Inc., a leading biopharmaceutical company creating next-generation immune therapies that deliver immune homeostasis.
Cleveland BioLabs, Inc Files Registration Statement on Form S-4 for Proposed Merger with Cytocom Inc
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.